http://www.fool.com/News/mft/2006/mft06082920.htm?ref=foolwatchMore Good News for RituxanBy Brian Lawler August 29, 2006 Yesterday, Genentech (NYSE: DNA) and partner Biogen Idec (Nasdaq: BIIB) announced positive interim results from a small phase 2 trial testing the company's blockbuster drug, Rituxan, for the treatment of multiple sclerosis.........
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra